Sign In
Buy CYRX
$16.50
+0.760 (+4.83%)
At Close: Jun 03, 2026
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("C
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("C
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("C
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("C
LOS ANGELES, CA / ACCESSWIRE / May 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("C
LOS ANGELES, CA / ACCESSWIRE / May 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("C
LOS ANGELES, CA / ACCESSWIRE / May 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("C
LOS ANGELES, CA / ACCESSWIRE / May 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cr
LOS ANGELES, CA / ACCESSWIRE / May 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cr
Cryoport, Inc. (CYRX) Q1 2024 Earnings Call Transcript
09:50pm, Tuesday, 07'th May 2024
Cryoport, Inc. (NASDAQ:CYRX ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Ex
Cryoport Reports First Quarter 2024 Financial Results
04:08pm, Tuesday, 07'th May 2024
Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675 global clinical trials
LOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cr
LOS ANGELES, CA / ACCESSWIRE / May 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cr
Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024
08:30am, Tuesday, 30'th Apr 2024
NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report finan
Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline
11:06am, Thursday, 25'th Apr 2024
CryoPort (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
